|
Trial and experimental group
|
Number of mice
|
0, 2, 4 wpv b
|
6-wpv b
|
1-wpc c
|
1-11 wpc c(80-dpc)
|
|---|
| | |
Vaccination
|
Cytokine assay
|
Challenge
|
Larval recovery
|
Mortality
|
|---|
|
(Trial I)
| |
(3 times per group)
|
(No. a)
|
(No. a, d)
|
(No. a)
|
(No. a)
|
|---|
|
rBsc-PYP-1/FCA/PBS
|
30
|
rBsc-PYP-1 (FCA plus PBS)
|
10
|
20
|
10
|
10
|
|
FCA/PBS
|
30
|
FCA plus PBS
|
10
|
20
|
10
|
10
|
|
PBS
|
30
|
PBS
|
10
|
20
|
10
|
10
|
|
Trial and experimental group
|
Number of mice
|
0, 2, 4 wpv
b
|
5-wpv
b
|
6-wpv
b
|
1-wpc
c
|
1-12 wpc
c
(80-dpc)
|
| | |
Vaccination
|
Challenge
|
Cytokine assay
|
Larval recovery
|
Mortality
|
|
(Trial II)
| |
(3 times per group)
|
(No.
a
)
|
(No.
a, e
)
|
(No.
a, f
)
|
(No.
a
)
|
|
rBsc-PYP-1/FCA/PBS
|
30
|
rBsc-PYP-1 (FCA plus PBS)
|
20
|
10
|
10
|
-
|
|
FCA/PBS
|
30
|
FCA plus PBS
|
20
|
10
|
10
|
-
|
|
PBS
|
30
|
PBS
|
20
|
10
|
10
|
-
|
- a Number of mice involved in this assay.
- b Week(s) post-vaccination.
- c Week(s) post-challenge.
- d Number of remaining mice in each experimental group after “Cytokine assay” and used for the subsequent determinations of “Larval recovery” and “Mortality”.
- e Number of remaining mice in each experimental group after “Challenge”.
- f Number of mice derived from “Challenge”.
